… We hypothesized that erlotinib would be efficacious in the adjuvant setting. Patients and …
Our hypothesis that this subset of patients might benefit from adjuvant erlotinib was based on …

… (RADIANT) trial investigated the efficacy of 2 years of adjuvant erlotinib versus placebo in
patients with resected NSCLC who had overexpression of EGFR protein by …

… comparing erlotinib versus placebo, both preceded by adjuvant chemotherapy in patients with
… to change current standards of adjuvant treatment for patients with EGFR-mutant NSCLC. …

… placebo as adjuvant therapy in patients with completely resected stage IB–IIIA NSCLC.
However, gefitinib did not show superiority over placebo in … low proportion of patients with EGFR-…

… comparing adjuvant gefitinib versus placebo in patients with … placebo in unselected patients
with inoperable stage III NSCLC. As a result, BR19 accrued 503 of planned 1160 patients …

… Subgroup analyses limited to the EGFR mutation-positive group did not show prolonged
survival (the median survival was not reached in both erlotinib- and placebo-treated patients; …

… In the absence of disease progression, chemotherapy was continued for a maximum of six
cycles, after which time patients continued to receive erlotinib or placebo monotherapy until …

7535 Background: We describe treatment duration and safety in the safety full analysis set (sFAS)
and in the subset of pts with EGFR del19 and L858R mutations (EGFR M+). Methods: …

… efficacy of 3-year osimertinib versus placebo for patients with completely resected EGFR-mutant
NSCLC13 further reflects the efficacy of EGFR-TKIs in adjuvant targeted therapy. …

… We performed this meta-analysis to compare adjuvant EGFR-TKIs with a placebo or adjuvant
… In the EVAN trial, adjuvant erlotinib was compared with adjuvant vinorelbine plus cisplatin …